Details for Patent: 11,944,612
✉ Email this page to a colleague
Which drugs does patent 11,944,612 protect, and when does it expire?
Patent 11,944,612 protects OXBRYTA and is included in two NDAs.
This patent has ten patent family members in eight countries.
Drugs Protected by US Patent 11,944,612
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Global Blood Theraps | OXBRYTA | voxelotor | TABLET, FOR SUSPENSION;ORAL | 216157-001 | Dec 17, 2021 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 10 | ⤷ Subscribe | ||||
Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-002 | Oct 14, 2022 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 10 | ⤷ Subscribe | ||||
Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-001 | Nov 25, 2019 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 10 | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,944,612
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Brazil | 112018011272 | ⤷ Subscribe | |||
European Patent Office | 3383392 | ⤷ Subscribe | |||
Israel | 259798 | ⤷ Subscribe | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |